小剂量尿激酶与奥扎格雷钠联合治疗进展性脑梗死的有效性及安全性分析  

Analysis of the efficacy and safety of low-dose urokinase combined with ozagrel in treatment of progressive cerebral infarction

作　　者：郑树旺[1] 

机构地区：[1]山东省安丘市人民医院,262100

出　　处：《中国实用医刊》2016年第20期28-29,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨小剂量尿激酶联合奥扎格雷钠治疗进展性脑梗死患者的临床疗效和安全性。方法选择2012年12月至2014年12月100例进展性脑梗死患者进行研究，将其随机分为研究组和对照组，每组50例。对照组患者采用低分子右旋糖酐和银杏叶注射液静脉滴注进行治疗，研究组患者在对照组的治疗基础上加用小剂量尿激酶和奥扎格雷钠进行联合治疗。观察两组患者的神经功能缺损情况和不良反应发生情况，并进行对比分析。结果研究组患者治疗的总有效率（94．0％）明显高于对照组（74．0％），差异有统计学意义（P〈0．05）。结论小剂量尿激酶联合奥扎格雷钠治疗进展性脑梗死患者具有良好的治疗效果，不良反应轻微，值得推广应用。Objective To investigate the clinical efficacy and safety of low dose of urokinase combined with sodium ozagrel in treatment of progressive cerebral infarction patients. Methods From 2012 December to December 2014, 100 patients with progressive cerebral infarction were randomly divided into study group and control group with 50 cases in each group. The control group was treated with low molecular dextran and ginkgo leaf injection for treatment, and patients in the study group were treated with low dose urokinase and sodium ozagrel treatment. The neurological condition and adverse reactions of the two groups were detected, analyzed and compared. Results The total efficiency of the patients in study group （94.0%） was significantly higher than that in the control group （74.0%）, and the differences were significant （P 〈 0. 05 ）. Conclusions Low dose of urokinase combined with sodium ozagrel has good effect on progressive cerebral infarction patients, and with mild adverse reactions, so it is worthy of popularization and application.

关 键 词：尿激酶 奥扎格雷钠 进展性脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学]